Paper · S7558
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy
This 2015 review discusses mass cytometry as a possible aid to rheumatic-disease research. Its preliminary illustration compares one patient with one healthy control; concurrent treatment and assay timing limit interpretation. The authors explicitly consider residual drug neutralizing added TNF as an alternative to changed cell signaling. The illustration does not establish a validated biomarker or clinical recommendation. Nolan is a verified coauthor, while detailed individual contribution roles are not supplied.
Read the paper at ebi.ac.ukWhat we checked
All 123 supplied XML units, 66 references and two nested captions were read. Fourteen glossary terms omitted by the initial partition were separately read and the native text audit found no remaining meaningful gaps. Both meaningful native JPEG figures, six SPADE panels, 63 paired histogram relationships and a small header crop were viewed. The native PMCID is PMC4436107.1; this is a review with one patient/control illustration, not a large clinical trial. No separate supplements are advertised.
Complete supplied review text and figures read
How we check sources
Not checked yet
- Original article-layout PDF, complete version history, raw data, code and cited full texts were not inspected. Some tiny axis glyphs, exact unprinted values and complete marker-panel composition remain unknown.
- A plural caption does not supply additional patients. The 19 surface-marker versus total-panel descriptions and apparently duplicated NK subgroup headings remain unresolved.
- Concurrent steroids and methotrexate, drug carryover, changing cytokine environment and phosphorylation timing are possible explanations. Sensitivity, specificity and independent clinical validation are not established.
Source limitations
- Fluidigm and SmartTube interests are reported. Source-era instrument capacity and funding do not establish current performance, government programme access or UAP findings.
Cite this record
Nitya Nair, Henrik E. Mei, Shih-Yu Chen, Matthew Hale, Garry P. Nolan, Holden T. Maecker, Mark Genovese, C. Garrison Fathman, Chan C. Whiting. Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy. May 18, 2015. BioParity S7558. https://bioparity.io/sources/S7558Record data (JSON)